ReP USP - Resultado da busca

Artigo de periodico
Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) (2021)
Grossi, Francesco; Jaskiewicz, Piotr; Ferreira, Marion; Czyzewicz, Grzegorz; Kowalski, Dariusz; Ciuffreda, Libero; Garcia-gomez, Ramon; Caruso, Salvatore; Bosch-barrera, Joaquim; Gautier, Stephanie; Castro Junior, Gilberto de Castro
Fonte: Therapeutic advances in medical oncology. Unidade: FM
Assuntos: ESTUDOS PROSPECTIVOS, NEOPLASIAS PULMONARES (TERAPIA), SOBREVIVÊNCIA LIVRE DE DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GROSSI, Francesco et al. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic advances in medical oncology, v. 13, 2021Tradução . . Disponível em: https://doi.org/10.1177/17588359211022905. Acesso em: 22 ago. 2024.
APA
Grossi, F., Jaskiewicz, P., Ferreira, M., Czyzewicz, G., Kowalski, D., Ciuffreda, L., et al. (2021). Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic advances in medical oncology, 13. doi:10.1177/17588359211022905
NLM
Grossi F, Jaskiewicz P, Ferreira M, Czyzewicz G, Kowalski D, Ciuffreda L, Garcia-gomez R, Caruso S, Bosch-barrera J, Gautier S, Castro Junior G de C. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) [Internet]. Therapeutic advances in medical oncology. 2021 ; 13[citado 2024 ago. 22 ] Available from: https://doi.org/10.1177/17588359211022905
Vancouver
Grossi F, Jaskiewicz P, Ferreira M, Czyzewicz G, Kowalski D, Ciuffreda L, Garcia-gomez R, Caruso S, Bosch-barrera J, Gautier S, Castro Junior G de C. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) [Internet]. Therapeutic advances in medical oncology. 2021 ; 13[citado 2024 ago. 22 ] Available from: https://doi.org/10.1177/17588359211022905
Trabalho de evento-resumo periodico
High-grade extrapulmonary neuroendocrine carcinomas and small cell lung cancer: Different entities, same treatment (2015)
Rego, Juliana Florinda De Mendonga; Medeiros, Raphael Salles S.; Braghiroli, Maria Ignez Freitas Melro; Galvao, Breno; Bezerra Neto, Joao Evangelista; Munhoz, Rodrigo Ramella; Guerra, Juliana Mariotti; Kimura, Lidia; Nonogaki, Suely; Pfiffer, Tulio Eduardo Flesch; Castro, Gilberto; Hoff, Paulo Marcelo; Rocha Filho, Duilio; Costa, Frederico; Riechelmann, Rachel Pimenta
Fonte: Journal of Clinical Oncology. Nome do evento: ASCO Annual Meeting. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES (TERAPIA), BIOMARCADORES, CARCINOMA NEUROENDÓCRINO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REGO, Juliana Florinda De Mendonga et al. High-grade extrapulmonary neuroendocrine carcinomas and small cell lung cancer: Different entities, same treatment. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15176?sid=d383ce87-0bfa-4a25-b2d7-df3d450bdf33. Acesso em: 22 ago. 2024. , 2015
APA
Rego, J. F. D. M., Medeiros, R. S. S., Braghiroli, M. I. F. M., Galvao, B., Bezerra Neto, J. E., Munhoz, R. R., et al. (2015). High-grade extrapulmonary neuroendocrine carcinomas and small cell lung cancer: Different entities, same treatment. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15176?sid=d383ce87-0bfa-4a25-b2d7-df3d450bdf33
NLM
Rego JFDM, Medeiros RSS, Braghiroli MIFM, Galvao B, Bezerra Neto JE, Munhoz RR, Guerra JM, Kimura L, Nonogaki S, Pfiffer TEF, Castro G, Hoff PM, Rocha Filho D, Costa F, Riechelmann RP. High-grade extrapulmonary neuroendocrine carcinomas and small cell lung cancer: Different entities, same treatment [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 ago. 22 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15176?sid=d383ce87-0bfa-4a25-b2d7-df3d450bdf33
Vancouver
Rego JFDM, Medeiros RSS, Braghiroli MIFM, Galvao B, Bezerra Neto JE, Munhoz RR, Guerra JM, Kimura L, Nonogaki S, Pfiffer TEF, Castro G, Hoff PM, Rocha Filho D, Costa F, Riechelmann RP. High-grade extrapulmonary neuroendocrine carcinomas and small cell lung cancer: Different entities, same treatment [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2024 ago. 22 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15176?sid=d383ce87-0bfa-4a25-b2d7-df3d450bdf33
Artigo de periodico
Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells (2014)
Teixeira, Sarah Fernandes; Azevedo, Ricardo Alexandre de; Salomon, Maria Alejandra Clavijo; Jorge, Salomão Dória; Levy, Débora; Bydlowski, Sérgio Paulo; Rodrigues, Cecília Pessoa; Pizzo, Célia Regina; Barbuto, José Alexandre Marzagão ; Ferreira, Adilson Kleber
Fonte: Biomedicine & Pharmacotherapy. Unidades: FM, ICB
Assuntos: NEOPLASIAS PULMONARES (TERAPIA), APOPTOSE, FÁRMACOS (SISTEMA RESPIRATÓRIO), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TEIXEIRA, Sarah Fernandes et al. Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells. Biomedicine & Pharmacotherapy, v. 68, n. 8, p. 1015-1022, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.biopha.2014.09.007. Acesso em: 22 ago. 2024.
APA
Teixeira, S. F., Azevedo, R. A. de, Salomon, M. A. C., Jorge, S. D., Levy, D., Bydlowski, S. P., et al. (2014). Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells. Biomedicine & Pharmacotherapy, 68( 8), 1015-1022. doi:10.1016/j.biopha.2014.09.007
NLM
Teixeira SF, Azevedo RA de, Salomon MAC, Jorge SD, Levy D, Bydlowski SP, Rodrigues CP, Pizzo CR, Barbuto JAM, Ferreira AK. Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells [Internet]. Biomedicine & Pharmacotherapy. 2014 ; 68( 8): 1015-1022.[citado 2024 ago. 22 ] Available from: https://doi.org/10.1016/j.biopha.2014.09.007
Vancouver
Teixeira SF, Azevedo RA de, Salomon MAC, Jorge SD, Levy D, Bydlowski SP, Rodrigues CP, Pizzo CR, Barbuto JAM, Ferreira AK. Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells [Internet]. Biomedicine & Pharmacotherapy. 2014 ; 68( 8): 1015-1022.[citado 2024 ago. 22 ] Available from: https://doi.org/10.1016/j.biopha.2014.09.007
Artigo de periodico
The lung adenocarcinoma guidelines: what to be considered by surgeons (2014)
Sardenberg, Rodrigo A. S.; Mello, Evandro Sobroza; Younes, Riad N.
Fonte: The Journal of Thoracic Disease. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES (TERAPIA), PROGNÓSTICO, ADENOCARCINOMA (CLASSIFICAÇÃO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SARDENBERG, Rodrigo A. S. e MELLO, Evandro Sobroza e YOUNES, Riad N. The lung adenocarcinoma guidelines: what to be considered by surgeons. The Journal of Thoracic Disease, v. 6, n. S5, p. S561-S567, 2014Tradução . . Disponível em: https://doi.org/10.3978/j.issn.2072-1439.2014.08.25. Acesso em: 22 ago. 2024.
APA
Sardenberg, R. A. S., Mello, E. S., & Younes, R. N. (2014). The lung adenocarcinoma guidelines: what to be considered by surgeons. The Journal of Thoracic Disease, 6( S5), S561-S567. doi:10.3978/j.issn.2072-1439.2014.08.25
NLM
Sardenberg RAS, Mello ES, Younes RN. The lung adenocarcinoma guidelines: what to be considered by surgeons [Internet]. The Journal of Thoracic Disease. 2014 ; 6( S5): S561-S567.[citado 2024 ago. 22 ] Available from: https://doi.org/10.3978/j.issn.2072-1439.2014.08.25
Vancouver
Sardenberg RAS, Mello ES, Younes RN. The lung adenocarcinoma guidelines: what to be considered by surgeons [Internet]. The Journal of Thoracic Disease. 2014 ; 6( S5): S561-S567.[citado 2024 ago. 22 ] Available from: https://doi.org/10.3978/j.issn.2072-1439.2014.08.25
Trabalho de evento-resumo periodico
Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer (2013)
Colombo, Natalia; Parra, Edwin R.; Gelain, Daniel P.; Schnorr, Carlos E.; Kolling, Eduardo; Grisólia, César K.; Hage, Marcia; Barbeiro, Denise F.; Capelozzi, Vera L.
Fonte: Journal of thoracic oncology. Nome do evento: World Conference on Lung Cancer. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES (TERAPIA), MODELOS ANIMAIS, PLANTAS MEDICINAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COLOMBO, Natalia et al. Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 22 ago. 2024. , 2013
APA
Colombo, N., Parra, E. R., Gelain, D. P., Schnorr, C. E., Kolling, E., Grisólia, C. K., et al. (2013). Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.
NLM
Colombo N, Parra ER, Gelain DP, Schnorr CE, Kolling E, Grisólia CK, Hage M, Barbeiro DF, Capelozzi VL. Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer. Journal of thoracic oncology. 2013 ; 8 S742-S743.[citado 2024 ago. 22 ]
Vancouver
Colombo N, Parra ER, Gelain DP, Schnorr CE, Kolling E, Grisólia CK, Hage M, Barbeiro DF, Capelozzi VL. Pequi fruit (Caryocar Brasiliense Camb) protects against oxidative stress induced by urethane in a experimental model of lung cancer. Journal of thoracic oncology. 2013 ; 8 S742-S743.[citado 2024 ago. 22 ]

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos